GlucoTrack, Inc. (NASDAQ:GCTK) Short Interest Update

GlucoTrack, Inc. (NASDAQ:GCTK) was the recipient of a significant decline in short interest in August. As of August 31st, there was short interest totaling 24,951 shares, a decline of 85.0% from the August 15th total of 165,864 shares. Based on an average daily trading volume, of 207,650 shares, the days-to-cover ratio is presently 0.1 days. Approximately 3.8% of the shares of the stock are short sold.

Institutional Trading of GlucoTrack

A number of institutional investors have recently bought and sold shares of the company. Ikarian Capital LLC acquired a new stake in GlucoTrack in the fourth quarter valued at $177,000. Boothbay Fund Management LLC purchased a new position in shares of GlucoTrack in the fourth quarter valued at $52,000. Finally, Bank of America Corp DE raised its stake in shares of GlucoTrack by 102,125.0% during the 2nd quarter. Bank of America Corp DE now owns 4,089 shares of the company’s stock worth $25,000 after buying an additional 4,085 shares during the last quarter. 10.92% of the stock is currently owned by hedge funds and other institutional investors.

GlucoTrack Price Performance

Shares of GCTK stock traded down $0.68 during midday trading on Friday, reaching $2.55. 740,839 shares of the company traded hands, compared to its average volume of 137,657. The firm’s 50 day simple moving average is $5.40 and its two-hundred day simple moving average is $9.66. The firm has a market cap of $1.80 million, a PE ratio of -0.02 and a beta of 0.62. The company has a debt-to-equity ratio of 0.08, a current ratio of 0.46 and a quick ratio of 0.46. GlucoTrack has a 1-year low of $2.26 and a 1-year high of $212.10.

Analyst Ratings Changes

GCTK has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GlucoTrack in a report on Friday, July 17th. Wall Street Zen raised GlucoTrack from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, GlucoTrack has an average rating of “Sell”.

GlucoTrack Company Profile

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc and changed its name to GlucoTrack, Inc in November 2021. GlucoTrack, Inc was founded in 2001 and is based in Rutherford, New Jersey.